Get the Daily Brief
Latest Biotech News
Ferritin bridge strengthens CAR‑T engagement – a non‑genetic fix for relapse
Researchers at the Institute of Process Engineering, Chinese Academy of Sciences, introduced a ferritin‑based aggregation cell engager (FACE) that augments CAR‑T cell avidity without...
Xenon’s epilepsy pill slashes seizures — phase 3 blowout
Xenon Pharmaceuticals announced Phase 3 X‑Tole2 results showing azetukalner reduced focal‑onset seizure frequency by 53.2% at the 25 mg dose versus placebo—an effect the company characterized as...
Roche’s oral SERD fails first‑line test — ripples across the oral SERD field
Roche’s Phase 3 PersevERA study of the oral SERD giredestrant missed its primary progression‑free survival endpoint in the first‑line ER‑positive, HER2‑negative breast cancer setting, the company...
Ipsen pulls Tazverik after trial monitors spot secondary blood cancers
Ipsen announced a voluntary withdrawal of Tazverik (tazemetostat) from the market and halted ongoing clinical studies after an independent data monitoring committee identified cases of secondary...
Verily and Samsung link wearables to trials — AI also matches doctors to studies
Verily and Samsung agreed to integrate Galaxy smartwatch data into Verily’s Pre platform to provide an end‑to‑end system for deploying wearables in clinical research, collecting passive...
Novo, Hims strike deal to curb compounding and widen GLP‑1 access
Novo Nordisk and telehealth firm Hims & Hers reached an agreement under which Novo will supply its GLP‑1 medicines through Hims at the same prices other telehealth providers offer, and Hims will...
In‑vivo CAR‑T and predictive biomarkers: two fronts for widening cell therapy access
Industry attention is splitting between in‑vivo CAR‑T strategies that aim to reprogram T cells inside patients and biomarker research that predicts ex‑vivo CAR‑T outcomes. In‑vivo CAR‑T...
WHO to recommend near‑patient molecular TB tests and tongue swabs
The World Health Organization will issue updated TB diagnostics guidance recommending a new class of near‑point‑of‑care molecular tests with lower unit costs, use of tongue swab sampling for...
Vertex kidney drug hits Phase 3 goal – best‑in‑class hopes rise
Vertex reported positive late‑stage results for a drug it acquired, showing a roughly 50% reduction in a key biomarker for IgA nephropathy in a Phase 3 study. The company said the data match or...
Xenon’s epilepsy pill crushes Phase 3 target: seizure rates halved
Xenon Pharmaceuticals announced Phase 3 X‑Tole2 results for azetukalner showing a 53.2% placebo‑adjusted reduction in focal onset seizure frequency at the 25 mg dose and strong tolerability at the...
Bristol Myers’ CELMoD mezigdomide clears Phase 3 — multiple myeloma PFS improves
Bristol Myers Squibb reported that mezigdomide, an oral CELMoD acquired through past transactions, met its primary endpoint in a late‑stage study of relapsed or refractory multiple myeloma,...
Ipsen pulls Tazverik after safety signals — market withdrawal and trial halts
Ipsen announced an immediate withdrawal of tazemetostat (Tazverik) from the U.S. market and suspension of ongoing clinical studies after an independent data monitoring committee identified cases...
Roche’s giredestrant flunks PersevERA — first‑line oral SERD setback
Roche reported that giredestrant missed the primary progression‑free survival endpoint in the PersevERA Phase 3 trial as a first‑line therapy for ER‑positive, HER2‑negative advanced breast cancer....
Agilent snaps up Biocare for $950M to expand pathology reach
Agilent Technologies agreed to acquire Biocare Medical for $950 million in cash to broaden its pathology portfolio with immunohistochemistry (IHC), in situ hybridization (ISH), FISH assays and...
FDA updates biosimilar Q&As: reissues guidance and posts revised draft — clarity on BPCI Act
The U.S. Food and Drug Administration issued a pair of documents clarifying its interpretation of the Biologics Price Competition and Innovation Act (BPCI Act). The agency reissued its final...
Ferritin 'FACE' platform boosts CAR‑T avidity without re‑engineering receptors
Researchers at the Institute of Process Engineering (Chinese Academy of Sciences) published a Cell paper introducing the ferritin aggregation cell engager (FACE), a biomimetic, ferritin‑based...
Verily and Samsung team to feed Galaxy smartwatch data into clinical trials
Verily and Samsung announced a partnership to integrate Galaxy smartwatch sensor data into Verily’s Pre platform to support clinical trials. The collaboration aims to create an end‑to‑end system...
DocTr AI matches doctors to trials with 58% higher accuracy — trial site selection gets smarter
A Nature Health study introduced DocTr, an AI system that recommends investigators and sites for clinical trials by analyzing patient encounter data, unstructured protocol documents, and...
Azetukalner cuts focal seizures 53% – Xenon aims Q3 filing
Xenon Pharmaceuticals reported Phase 3 X‑Tole2 results showing azetukalner reduced focal onset seizure frequency by 53.2% at the 25 mg dose and 34.5% at 15 mg versus placebo. The company said the...
Vertex’s acquired drug halves IgA marker – late‑stage win
Vertex reported that the drug it acquired in a multibillion‑dollar deal met its primary endpoint in a Phase 3 study for IgA nephropathy, cutting a key disease marker by roughly 50%. The company...